Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat.
OBJECTIVE
To compare the effectiveness of brinzolamide 1%, brimonidine 0.2%, acetazolamide 250 mg, intracameral acetylcholine, and timolol 0.5% in preventing intraocular pressure (IOP) peaks during the early period after phacoemulsification in which sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) was used as the ophthalmic viscosurgical device (OVD).


METHODS
Department of Ophthalmology, Baskent University Medical Faculty, Ankara, Turkey.


METHODS
This prospective randomized study comprised 185 eyes of 185 patients with uncomplicated cataract scheduled for phacoemulsification using Viscoat as the OVD. Patients were randomly assigned to 1 of 6 groups: postoperative application of topical brinzolamide 1%, brimonidine 0.2%, oral acetazolamide 250 mg, intracameral acetylcholine, timolol 0.5%, or no ocular hypotensive agent (control group). The IOP was measured at baseline (preoperatively) as well as 6 hours, 20 to 24 hours, and 1 week after surgery.


RESULTS
The mean preoperative IOP values were not significantly different between the groups. Six hours and 20 to 24 hours postoperatively, the mean IOP was significantly lower in all groups receiving an ocular hypotensive agent than in the control group (P<.01). Six hours after surgery, the mean IOP significantly increased in all groups but was higher in the control group. At 20 to 24 hours, the mean IOP decreased significantly in all ocular hypotensive agent groups but remained significantly high in the control group. One week after surgery, there were no significant differences between the groups.


CONCLUSIONS
Brinzolamide, brimonidine, acetazolamide, intracameral acetylcholine, and timolol had similar effects in reducing IOP increases after phacoemulsification performed using Viscoat.
Borazan
Mehmet
M
Department of Ophthalmology, Baskent University School of Medicine, Ankara, Turkey. borazan74@hotmail.com
Karalezli
Aylin
A
Akman
Ahmet
A
Akova
Yonca Aydin
YA
D000086:Acetazolamide / Q000008:administration & dosage; D000109:Acetylcholine / Q000008:administration & dosage; D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D000068438:Brimonidine Tartrate; D002807:Chondroitin / Q000627:therapeutic use*; D002809:Chondroitin Sulfates; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D007429:Intraocular Pressure / Q000187:drug effects*; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000517:prevention & control*; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D013843:Thiazines / Q000008:administration & dosage; D013999:Timolol / Q000008:administration & dosage; D014065:Tonometry, Ocular
D000959:Antihypertensive Agents; D004338:Drug Combinations; D011810:Quinoxalines; D013449:Sulfonamides; D013843:Thiazines; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D000068438:Brimonidine Tartrate; D013999:Timolol; D006820:Hyaluronic Acid; D002807:Chondroitin; D002809:Chondroitin Sulfates; C111827:brinzolamide; D000109:Acetylcholine; D000086:Acetazolamide